Heron Therapeutics Inc (HRTX) was Initiated by Cantor Fitzgerald to “Buy”. Cantor Fitzgerald advised their investors in a research report released on May 3, 2016.
Heron Therapeutics Inc opened for trading at $21.67 and hit $22.36 on the upside on Monday, eventually ending the session at $22.33, with a gain of 4.15% or 0.89 points. The heightened volatility saw the trading volume jump to 4,35,695 shares. Company has a market cap of $809 M.
In a different news, on Apr 21, 2016, Robert Rosen (President) sold 200,000 shares at $23.32 per share price. According to the SEC, on Jun 3, 2015, Kimberly Manhard (director) sold 13,208 shares at $22.38 per share price. On Mar 9, 2015, Paul Marshall (SVP, Technical Operations) sold 70,000 shares at $14.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Heron Therapeutics Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company’s product candidate SUSTOL (granisetron injection extended release) is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company’s product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort or eliminate the drawbacks of current therapies. The Company’s other product candidates include HTX-019 for CINV which is in Preclinical state; HTX-011 for Post-operative pain management which is in Phase I trials and HTX-003 for chronic pain management which is in Preclinical state.